Paradigm Shift in the Treatment of Head and Neck Cancer: The Role of Neoadjuvant Chemotherapy

Posner, Marshall R.

doi:10.1634/theoncologist.10-90003-11

Cited by 58 publications

(30 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nowadays, researches have been substantially focused on the chemotherapy for tumors (Posner, 2005;Takiuchi, 2007). Fluorouracil is one of the standard chemotherapeutic drugs in the treatment of this disease (van Hazel et al, 2009).…”

Section: Introductionmentioning

confidence: 99%

Apoptosis of Colorectal Cancer UTC116 Cells Induced by Cantharidinate

Liu

Gao²,

Xu³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Effects of Cantharidinate on apoptosis of human colorectal cancer UTC-116 cells were investigated by means of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay, H and E staining, flow cytometry, and Raman Spectra analysis. The results showed Cantharidinate to exert inhibitory action on proliferation of human colorectal cancer UTC-116 cells, inducing apoptosis, arresting cells in G1 phase, with decline of S and G2 phases. In addition, the results of Raman spectrum showed significant changes in the UTC-116 cells chemical structure with stretching after the application of Cantharidinate. Taken together, these results suggest that the treatment of human colorectal cancer with Cantharidinate may be associated with multiple molecular mechanisms for apoptosis. Furthermore, similar to fluorouracil, Cantharidinate should be considered as novel assistant drug for controlling the growth of human colorectal cancer UTC-116 cells.

show abstract

Section: Introductionmentioning

confidence: 99%

Apoptosis of Colorectal Cancer UTC116 Cells Induced by Cantharidinate

Liu

Gao²,

Xu³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Pendant plusieurs anné es, l'association de cisplatine et de 5-fluorouracile (PF) a é té un traitement standard en chimiothé rapie d'induction, permettant d'obtenir 60 à 90 % de ré ponse objective [55]. Dans les cas de cancer du larynx ou de l'hypopharynx localement avancé s, elle peut permettre une pré servation d'organe en é vitant des laryngectomies totales, sans compromettre la survie.…”

Section: Pré Servation Laryngé Eunclassified

“…L'association des deux approches thé rapeutiques pourrait peut-ê tre permettre de gagner davantage à la fois sur le contrô le local et à distance [55]. Associations thé rapie ciblé e-radiothé rapie…”

Section: Pré Servation Laryngé Eunclassified

Carcinomes des voies aérodigestives supérieures: nouvelles approches en radiothérapie

Mazeron

Bourhis

2008

Oncologie

View full text Add to dashboard Cite

show abstract

“…years and approximately 30% of these develop metastatic disease (Posner 2005). The mainstay of chemotherapeutic treatment in SCC is the platinum-based drug, cisplatin, 5-fluorouracil (5-FU), taxanes, and anti-EGFR monoclonal antibody such as Cetuximab (Posner 2005;Bernier and Vrieling 2008;Panikkar, Astsaturov et al 2008;Specenier and Vermorken 2009).…”

mentioning

confidence: 99%

“…The mainstay of chemotherapeutic treatment in SCC is the platinum-based drug, cisplatin, 5-fluorouracil (5-FU), taxanes, and anti-EGFR monoclonal antibody such as Cetuximab (Posner 2005;Bernier and Vrieling 2008;Panikkar, Astsaturov et al 2008;Specenier and Vermorken 2009). Nonetheless, despite advances in treatment techniques, the 5-year survival rate still remains at around 55%.…”

mentioning

confidence: 99%

The role of E2F7 and E2F8 in squamous differentiation, UV- and chemotherapy-induced responses in keratinocytes

Rethinam¹

View full text Add to dashboard Cite

Among keratinocyte-derived squamous cell carcinoma (SCC), cutaneous SCC (CSCC) is the second most common cutaneous cancer type and the most common of the potentially fatal skin cancers. Approximately 90% of head and neck cancers are SCC (HNSCC) and HNSCC worldwide is the sixth most common cancer type afflicting mankind. While resectable disease may be treated by surgery with radiation or chemoradiation, there are still no curative options for advanced, unresectable disease. However, chemotherapy alone may offer a hope for unresectable, disseminated SCC, where 50-60% of patients have disease recurrence within 2 years and approximately 30% of these develop metastatic disease. The mainstay of chemotherapeutic treatment in SCC is the platinum-based drug, cisplatin, 5-fluorouracil (5-FU), taxanes, and anti-EGFR monoclonal antibody such as Cetuximab. Nonetheless, despite advances in treatment techniques, the 5-year survival rate still remains at around 55%.Therefore, there remains a lack of options for recurrent or metastatic disease.The E2F family of transcription factors has emerged as key regulators of proliferation, differentiation and response to stress and apoptotic stimuli in keratinocytes. Consistent with these roles, dysregulation of E2F expression/activity is a common occurrence in cancer and SCC in particular. Thus, better understanding of the E2F family of proteins is essential to establish how these processes are disrupted during SCC genesis. The E2F network exists as a complex map of interacting pathways, and the complete understanding of the E2F family will not be possible until physiological functions of newly identified inhibitory E2F proteins, E2F7 and E2F8, are fully revealed. I provide strong evidence, from in vitro experiments, that E2F7 plays a unique and non-redundant role in modulating UV-or chemotherapy-induced cytotoxicity whereas E2F8 has a unique and non-redundant capacity to regulate squamous differentiation. In addition, I report on a unique feedback loop between E2F1, E2F7 and E2F8 that highlights a previously unreported interdependent axis.With respect to E2F7-specific functions, my work characterised two previously unidentified pathways as therapeutic targets, E2F7/Sphk1/S1P/AKT and E2F7/RacGAP1/AKT, by which the transcription factor E2F7 suppresses doxorubicin specific sensitivity in SCC cells.Targeting these pathways has the potential to expand the clinical activity of existing chemotherapeutics. I provide, in vitro, in vivo and patient data in this study that shows that E2F7-dependent repression of doxorubicin sensitivity is mediated via the induction of Sphingosine kinase 1 (Sphk1) and Rac GTPase activating protein 1 (RacGAP1). These are iii both novel findings and have significant implications for drug resistant SCC. Specifically, Ishowed that (i) E2F7 is overexpressed in patient SCCs and inhibits sensitivity to doxorubicin, (ii) that E2F7-dependent doxorubicin resistance is mediated via E2F-dependent induction of Sphk1 leading to overproduction of Sphingosine-1-phosphate ...

show abstract

Paradigm Shift in the Treatment of Head and Neck Cancer: The Role of Neoadjuvant Chemotherapy

Cited by 58 publications

References 57 publications

Apoptosis of Colorectal Cancer UTC116 Cells Induced by Cantharidinate

Apoptosis of Colorectal Cancer UTC116 Cells Induced by Cantharidinate

Carcinomes des voies aérodigestives supérieures: nouvelles approches en radiothérapie

The role of E2F7 and E2F8 in squamous differentiation, UV- and chemotherapy-induced responses in keratinocytes

Contact Info

Product

Resources

About